# Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

> **NCT01009593** · PHASE3 · TERMINATED · sponsor: **Abbott** · enrollment: 1035 (actual)

## Conditions studied

- Hepatocellular Carcinoma Non-resectable
- Hepatocellular Carcinoma Recurrent
- Carcinoma, Hepatocellular
- Liver Diseases
- Neoplasms by Histologic Type
- Digestive System Neoplasms
- Carcinoma
- Liver Neoplasms
- Neoplasms
- Neoplasms by Site
- Digestive System Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial

## Interventions

- **DRUG:** ABT-869
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT01009593
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-01
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 1035 (ACTUAL)
- **Why stopped:** See termination reason in detailed description
- **Last updated:** 2012-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01009593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01009593, "Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01009593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*